AstraZeneca PLC (AZN)
Company Info
US0463531089
046353108
May 12, 1993
Highlights
$213.34B
$2.48
27.75
0.92
$54.98B
$44.75B
$17.70B
$61.24 - $86.46
$84.18
0.16%
0.70
Share Price Chart
Loading data...
Compare to other instruments
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
Performance Chart
Loading data...
Returns By Period
AstraZeneca PLC (AZN) returned 6.49% year-to-date (YTD) and -8.71% over the past 12 months. Over the past 10 years, AZN had an annualized return of 10.64%, just below the S&P 500 benchmark at 10.89%.
AZN
6.49%
1.81%
10.35%
-8.71%
7.65%
10.64%
^GSPC (Benchmark)
1.30%
12.79%
1.49%
12.35%
15.12%
10.89%
Monthly Returns
The table below presents the monthly returns of AZN, with color gradation from worst to best to easily spot seasonal factors. Returns are adjusted for dividends.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025 | 8.00% | 9.21% | -3.56% | -2.33% | -4.15% | 6.49% | |||||||
| 2024 | -1.05% | -2.24% | 5.60% | 12.00% | 2.82% | -0.04% | 1.49% | 11.38% | -11.08% | -8.68% | -4.96% | -3.11% | -0.62% |
| 2023 | -3.58% | 1.16% | 6.49% | 5.49% | -0.19% | -2.07% | 0.18% | -4.79% | -0.15% | -6.63% | 2.15% | 4.27% | 1.44% |
| 2022 | -0.07% | 6.32% | 8.97% | 0.09% | 0.12% | -0.62% | 0.24% | -5.15% | -12.09% | 7.24% | 15.58% | -0.25% | 19.16% |
| 2021 | 1.22% | -2.54% | 2.77% | 6.74% | 6.97% | 5.51% | -4.44% | 2.63% | 3.05% | 3.86% | -12.10% | 6.24% | 19.73% |
| 2020 | -2.33% | -8.23% | 1.96% | 17.06% | 4.44% | -3.13% | 5.46% | 1.20% | -2.14% | -8.47% | 5.54% | -5.57% | 3.12% |
| 2019 | -3.69% | 16.27% | -2.77% | -6.85% | -0.74% | 10.43% | 5.16% | 4.81% | -1.02% | 10.01% | -1.12% | 2.85% | 35.68% |
| 2018 | 1.04% | -2.71% | 5.36% | 1.60% | 4.22% | -5.19% | 11.45% | -0.91% | 3.21% | -2.00% | 2.68% | -4.62% | 13.77% |
| 2017 | -0.33% | 10.94% | 6.42% | -2.86% | 13.69% | -0.87% | -11.47% | 0.32% | 13.58% | 1.83% | -4.72% | 5.57% | 33.10% |
| 2016 | -5.10% | -8.20% | -1.78% | 2.84% | 2.56% | 1.65% | 13.08% | -2.64% | 0.15% | -13.82% | -7.70% | 4.51% | -15.90% |
| 2015 | 0.94% | -0.32% | -0.68% | 0.07% | -1.36% | -5.68% | 6.07% | -6.22% | 1.73% | 0.22% | 6.77% | -0.29% | 0.45% |
| 2014 | 6.96% | 9.77% | -4.25% | 21.84% | -8.67% | 2.92% | -2.05% | 5.80% | -6.01% | 2.10% | 1.69% | -5.11% | 23.55% |
Risk-Adjusted Performance
Risk-Adjusted Performance Rank
The current rank of AZN is 30, indicating average performance compared to other stocks on our website. Here’s a breakdown of how it compares using common performance measures.
Risk-Adjusted Performance Indicators
The charts below present risk-adjusted performance metrics for AstraZeneca PLC (AZN) and compare them to a chosen benchmark (^GSPC). These indicators evaluate an investment's returns against its associated risks.
Loading data...
Dividends
Dividend History
AstraZeneca PLC provided a 2.22% dividend yield over the last twelve months, with an annual payout of $1.53 per share. The company has been increasing its dividends for 8 consecutive years.
| Period | TTM | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend | $1.53 | $1.49 | $1.45 | $1.45 | $1.40 | $1.40 | $1.40 | $1.37 | $1.37 | $1.37 | $1.38 | $1.40 |
Dividend yield | 2.22% | 2.27% | 2.15% | 2.14% | 2.40% | 2.80% | 2.81% | 3.61% | 3.95% | 5.01% | 4.06% | 3.98% |
Monthly Dividends
The table displays the monthly dividend distributions for AstraZeneca PLC. The dividends shown in the table have been adjusted to account for any splits that may have occurred.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025 | $0.00 | $1.03 | $0.00 | $0.00 | $0.00 | $1.03 | |||||||
| 2024 | $0.00 | $0.99 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.50 | $0.00 | $0.00 | $0.00 | $0.00 | $1.49 |
| 2023 | $0.00 | $0.99 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.47 | $0.00 | $0.00 | $0.00 | $0.00 | $1.45 |
| 2022 | $0.00 | $0.99 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.47 | $0.00 | $0.00 | $0.00 | $0.00 | $1.45 |
| 2021 | $0.00 | $0.95 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.45 | $0.00 | $0.00 | $0.00 | $0.00 | $1.40 |
| 2020 | $0.00 | $0.95 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.45 | $0.00 | $0.00 | $0.00 | $0.00 | $1.40 |
| 2019 | $0.00 | $0.95 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.45 | $0.00 | $0.00 | $0.00 | $0.00 | $1.40 |
| 2018 | $0.00 | $0.93 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.44 | $0.00 | $0.00 | $0.00 | $0.00 | $1.37 |
| 2017 | $0.00 | $0.93 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.44 | $0.00 | $0.00 | $0.00 | $0.00 | $1.37 |
| 2016 | $0.00 | $0.93 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.44 | $0.00 | $0.00 | $0.00 | $0.00 | $1.37 |
| 2015 | $0.00 | $0.94 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.44 | $0.00 | $0.00 | $0.00 | $0.00 | $1.38 |
| 2014 | $0.95 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.45 | $0.00 | $0.00 | $0.00 | $0.00 | $1.40 |
Dividend Yield & Payout
Dividend Yield
AstraZeneca PLC has a dividend yield of 2.22%, which is quite average when compared to the overall market.
Payout Ratio
AstraZeneca PLC has a payout ratio of 44.65%, which is quite average when compared to the overall market. This suggests that AstraZeneca PLC strikes a balance between reinvesting profits for growth and paying dividends to shareholders.
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Loading data...
Worst Drawdowns
The table below displays the maximum drawdowns of the AstraZeneca PLC. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the AstraZeneca PLC was 48.94%, occurring on Mar 9, 2009. Recovery took 977 trading sessions.
The current AstraZeneca PLC drawdown is 20.37%.
Depth | Start | To Bottom | Bottom | To Recover | End | Total |
|---|---|---|---|---|---|---|
| -48.94% | Oct 26, 2006 | 594 | Mar 9, 2009 | 977 | Jan 24, 2013 | 1571 |
| -43.5% | Mar 4, 2002 | 127 | Aug 30, 2002 | 382 | Mar 9, 2004 | 509 |
| -34.31% | Apr 7, 1998 | 476 | Feb 24, 2000 | 94 | Jul 10, 2000 | 570 |
| -31.26% | Mar 10, 2004 | 221 | Jan 24, 2005 | 229 | Dec 19, 2005 | 450 |
| -29.82% | May 2, 2014 | 653 | Dec 1, 2016 | 272 | Jan 2, 2018 | 925 |
Volatility
Volatility Chart
The chart below shows the rolling one-month volatility.
Loading data...
Financials
Financial Performance
The chart below illustrates the trends in the financial health of AstraZeneca PLC over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.
Earnings Per Share
The chart presents the Earnings Per Share (EPS) performance of AstraZeneca PLC, comparing actual results with analytics estimates. In the past quarter, the company did not meet analyst expectations for EPS, resulting in a surprise of -16.3%.
Valuation
The Valuation section provides an overview of how AstraZeneca PLC is priced in the market compared to other companies in the Drug Manufacturers - General industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.
PE Ratio
The chart displays the Price-to-Earnings (P/E) ratio for AZN, comparing it with other companies in the Drug Manufacturers - General industry. Currently, AZN has a P/E ratio of 27.7. This P/E ratio is significantly higher than those of industry peers. This could indicate that the stock is overvalued or that investors expect strong future growth.
PEG Ratio
The chart shows the Price/Earnings to Growth (PEG) ratio for AZN compared to other companies in the Drug Manufacturers - General industry. AZN currently has a PEG ratio of 0.9. This PEG ratio is close to the industry average, suggesting the stock’s valuation is balanced against its growth outlook.
PS Ratio
This chart shows the Price-to-Sales (P/S) ratio for AZN relative to other companies in the Drug Manufacturers - General industry. Currently, AZN has a P/S ratio of 3.9. This P/S ratio falls within the average range for the industry, suggesting the stock is fairly valued based on its revenue.
PB Ratio
The chart illustrates the Price-to-Book (P/B) ratio for AZN in comparison with other companies in the Drug Manufacturers - General industry. Currently, AZN has a P/B value of 5.2. This P/B ratio is in line with the industry average, suggesting the stock is valued fairly in relation to its book value.
Income Statement
| TTM | |
|---|---|
Revenue | — |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
Operating Expenses | — |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
Income | — |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |